Stockscreener 앱 받기
1.0205
0.97%
-0.0095
전일 마감가:
$1.03
열려 있는:
$1.07
하루 거래량:
22,540
Relative Volume:
0.06
시가총액:
$3.13M
수익:
-
순이익/손실:
$-9.60M
주가수익비율:
-0.3229
EPS:
-3.16
순현금흐름:
$-8.96M
1주 성능:
+6.94%
1개월 성능:
+5.04%
6개월 성능:
-12.82%
1년 성능:
-23.88%
1일 변동 폭
$1.00
$1.1222
1주일 범위
$0.90
$1.16
52주 변동 폭
$0.8196
$1.5899
Artelo Biosciences Inc Stock (ARTL) Company Profile
명칭
Artelo Biosciences Inc
전화
858-925-7049
주소
505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA
ARTL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARTL
Artelo Biosciences Inc
|
1.02 | 3.13M | 0 | -9.60M | -8.96M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.17 | 125.74B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
600.04 | 61.57B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
612.14 | 36.40B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.90 | 30.36B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
245.57 | 24.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Artelo Biosciences Inc Stock (ARTL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-02-12 | 개시 | Ladenburg Thalmann | Buy |
Artelo Biosciences Inc 주식(ARTL)의 최신 뉴스
Artelo Biosciences (NASDAQ:ARTL) Shares Down 11.2% – What’s Next? - Defense World
Third Harmonic Bio (THRD) Plans Liquidation; Significant Search Surge in Biotech Sector | ARTL Stock News - GuruFocus
Artelo Biosciences (ARTL) Advances Novel Pain Therapy with Upcoming Data - GuruFocus
Artelo Biosciences (ARTL) Advances Cancer Therapy Pipeline - GuruFocus
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
D. Boral Capital Reaffirms Buy Rating for Artelo Biosciences (NASDAQ:ARTL) - Defense World
Artelo Biosciences stock hits 52-week low at $0.91 - Investing.com
Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025 - The Manila Times
New Data Reveals Artelo's FABP5 Inhibitor Could Transform Pain and Cancer Treatment - Stock Titan
Artelo Biosciences (ARTL) Projected to Post Earnings on Monday - Defense World
Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Update - Defense World
HC Wainwright Has Pessimistic View of ARTL FY2025 Earnings - Defense World
Artelo Biosciences Reports 2024 Financial Results and Clinical Progress - TipRanks
Artelo Biosciences (NASDAQ:ARTL) Given Buy Rating at HC Wainwright - Defense World
Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results - The Manila Times
ARTELO BIOSCIENCES, INC. SEC 10-K Report - TradingView
Can Artelo's Three Clinical Programs Overcome Its $9.8M Annual Loss? - StockTitan
Artelo Biosciences, Inc. (NASDAQ:ARTL) Sees Significant Increase in Short Interest - Defense World
Artelo Biosciences’ (ARTL) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Artelo Biosciences reports promising nonclinical CBD study - MSN
Analyzing Artelo Biosciences (NASDAQ:ARTL) & Rafael (NYSE:RFL) - Defense World
Artelo Biosciences Reports Positive ART12.11 Tablet Data Showing Improved Pharmacokinetics - Nasdaq
Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex® - GlobeNewswire
Revolutionary CBD Tablet Formulation Achieves Breakthrough Pharmacokinetic Results vs Epidiolex - StockTitan
Artelo Biosciences to Present its New Data on ART12.11 - GlobeNewswire
Artelo Biosciences to Present its New Data on ART12.11 Tablets Compared to Epidiolex at the IMCCB-25 Conference in Bern, Switzerland - The Manila Times
Artelo's CBD Innovation Matches Epidiolex PerformanceGroundbreaking Study Revealed - StockTitan
Artelo Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 - Marketscreener.com
Artelo Biosciences Announces Five Year Commitment To Sponsor The Young Investigator Award At The International Cannabinoid Research Society Annual Symposium - Marketscreener.com
Short Interest in Artelo Biosciences, Inc. (NASDAQ:ARTL) Drops By 42.2% - Defense World
Drug Designed to Treat Neuropathy Advances in Clinical Trials - Stony Brook University
Artelo Biosciences (NASDAQ:ARTL) Earns Buy Rating from D. Boral Capital - Defense World
Aemetis, Inc. (NASDAQ:AMTX) Holdings Trimmed by Jane Street Group LLC - Defense World
Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12 - The Manila Times
Artelo Biosciences Completes First Phase 1 Cohort for Novel FABP5 Pain Treatment ART26.12 - StockTitan
EXCLUSIVE: Artelo Biosciences Concludes First Cohort Of Healthy Volunteers Of FABP Inhibitor Program - Benzinga
Artelo Biosciences Holds Annual Meeting; Directors Re-Elected and Independent Auditor Appointment Ratified - Defense World
Artelo Biosciences stock hits 52-week low at $0.97 By Investing.com - Investing.com Canada
Artelo Biosciences stock hits 52-week low at $0.97 - Investing.com
Artelo presents Phase 1 data with ART27.13 in cancer-related anorexia - Yahoo Finance
Biotech's Parkinson's Drug Could Be Worth US$4B, Analyst Says - Streetwise Reports
Artelo Biosciences’ (ARTL) Buy Rating Reaffirmed at D. Boral Capital - Defense World
California Biopharma Shows Promising Phase 1 Data - Streetwise Reports
Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia - The Manila Times
Artelo's Cancer Drug Shows Breakthrough Results: 67% of Patients Reverse Weight Loss in Phase 1 Trial - StockTitan
Artelo Biosciences (ARTL) Stock Surges 5% Amid Strong Buy Ratings - GuruFocus.com
Artelo Biosciences (ARTL) Shares Drop Amidst Biotech Sector Move - GuruFocus.com
Artelo Biosciences (ARTL) Stock Surges Amid Strong Buy Ratings - GuruFocus.com
Artelo Biosciences to Present Key Drug Development Data at Major Cannabinoid Summit | ARTL Stock News - StockTitan
HC Wainwright Has Negative Outlook of ARTL FY2024 Earnings - Defense World
Artelo Biosciences Inc (ARTL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.63%
자본화:
|
볼륨(24시간):